Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + romidepsin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination of two anticancer drugs—paclitaxel (a microtubule inhibitor) and romidepsin (a class I histone deacetylase inhibitor). Paclitaxel disrupts cell division by stabilizing microtubules and preventing their depolymerization. Romidepsin inhibits histone deacetylases (HDACs), leading to increased acetylation of histones and non-histone proteins, resulting in altered gene expression that can induce apoptosis and inhibit tumor growth. The combination has shown synergistic effects in preclinical models of inflammatory breast cancer (IBC), effectively eliminating both primary tumors and metastatic lesions. Clinical trials are ongoing for metastatic IBC and advanced pancreatic ductal adenocarcinoma[1][2][3][4][6].
- Brand names
- Abraxane
- Other names
- nab-paclitaxel + romidepsin
02
Targets
HDAC1 (Histone Deacetylase 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + romidepsin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + romidepsin.